Synthesis of Pt(II) Complexes containing Flavin mononucleotide as Leaving Ligand and their Anticancer Activity

Flavin mononucleotide를 탈리기로한 백금 (II) 착체의 합성과 그 항암활성

  • 권영이 (숙명여자대학교 약학대학) ;
  • 황규자 (숙명여자대학교 약학대학)
  • Published : 1999.12.01

Abstract

A series of vitamin-containing Pt(II) complexes of the type [Pt (FMN) (L)] (FMN=flavin mononucleotide, L=ethylenediamine, 1,3-propanediamine, 1,4-bu-tanediamine) was synthesizd and characterized by IR, electronic absorption, elemental analysis and FAB=Mass. The coordination sites of FMN to Pt(II) ions were determined to be N(5) and O(6) with resultant chelate ring formation. Theses compounds have much better water solubility (30-35 mg/ml) than cisplatin (1 mg/ml). The anticancer activity of this vitamin-containing Pt(II) series was investigated by MTT assay against mouse and human leukemia cell lines in vitro. Among these compounds, FMN (1,4-butanediamine) Pt(II) having seven-membered ring structure as amine ligand showed moderate anticancer activity.

Keywords

References

  1. Nature v.205 Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode Rosenberg, B.;VanCamp, L.;Krigas, T.L.
  2. Nature v.222 Platinum Compounds : a New Class of Potent Antitumor Agents Rosenberg, B.;VanCamp, L:Trosko, J. E.;Mansour, V.H.
  3. Cnacer Chemother. Rep. v.57 Clinical trials of cis-Diamine dichloroplatinum (NSC-119875) Lippman, A. J.;Helson, C.;Krakoff, I. H.
  4. Ann. Intern. Med. v.100 Drugs Five Years Later Loehrer, P.J.;Einhorn, L. H.
  5. Semin. Oncol. v.11 Chemotherapy of Ovarian Cancer Ozols, R. F.;Young, R. C.
  6. J. Urol. v.120 cis-Diaminedichloroplatinum(II) (CD DP)in Advanced Bladder Cancer Soloway,M.S.
  7. Platinum and Other Metal Coordination Compouns in Cancer Chemotherapy Platinum, the Synergistic Drug; from Clinical Evidence to Laboratory Suggestions Fiorentino, M. V.;Ghiotto, C.
  8. Cancer Chemother. Pharmacol v.15 Phase II Trial of 5-Fluorouracil, Adriamycin and Cisplatin (FAP) in Advanced Gastric Cancer Wagener, D. J.;Yap, S. H.;Wobbes, T.;Burghouts, J.;van Darm, F. E.;Hillen, H. F.;Hoogendoorn, G. J.;Scheerder, H.;van der Vegt, S. G.
  9. Cancer Chemother. Rep. v.60 Comparative nephrotoxicity of platinum cnacer chemotherapeutic agent Ward, J. M.;Young, D. M.;Fauvie, K. A.;Wolpert, M. K.;Davis, R.;Gurano, A. M.
  10. Cancer Treat. Rep. v.63 Nephrotoxicity of diammine-dichloroplatinum(II) Krakoff, I. H.
  11. Jpn. J. Cancer Chemother. v.16 Phase II Study with Cisplatin in Advanced Stomach and Colon Carcinoma Ishibiki, K.;Kodaira, S.;Abe, O.;Yamamoto, K.;Ooci, T.;Fukaya, Y.;Kimura, K.;Takamatsu, K.;Ootsuka, E.;Sakabe, T.;Nishiyama, T.;Mioshima, Y.;Ogoshi, K.;Mitomi, T.
  12. Semin. Oncol. v.16 Pharmacologic Reversal of Drug Resistance in Ovarian Cancer Ozols, R. F.
  13. Int. J. Cancer v.41 Establishment and Characterization of Cisplatin-resistant Sublines of Human Lung Cancer Lines Hong, W. S.;Saijo, N.;Sassaki, Y.;Minato, K.;Nakano, H.;Nakagawa, K.;Fujiwara, Y.;Nomura, K.
  14. Cancer Treat. Rep. v.63 Rationale for Development of Platinum Analogs Burchenal, J. H.;Kalaher, K.;Dew, K.;Lokys, L.
  15. Biochimie. v.60 Selection of Potential Second Generation Platinum Compounds Wilkinson, R.;Cox, P.J.;Jone, M.;Harrap, K. R.
  16. Cancer Chemother. Pharmacol. v.9 Early Clinical Studies with cis-Diamine(1,1-cyclobutanedicarboxylato) Platinum (II) Calvert, A. H.;Harland, S. J.;Newell, D. R.;Siddik, Z. H.;Jones, A. C.;McEwain, T. J.;Raju, S.;Wiltshaw, E.;Smith, I. E.;Baker, J. M.;Peckham, M. J.;Harrap, K. R.
  17. Cancer Treat. Rev. v.12 no.SUP.A Results of NCI-Sponsored Phase I Trials with Carboplatin Foster, B. J.;Clagett-Carr, K.;Leyland-Jones, B.;Hoth, D.
  18. Cancer Treat. Rev. v.12 no.SUP.A Carboplatin : Future Directions Carter, S. K.;Canetta, R.;Rozencweig, M.
  19. Cancer Treat. Rev. v.12 no.SUP.A Preclinal Studies Identifying Carboplatin as Visible Cisplatin Alternative Harrap, K. R.
  20. Br. J. Cancer v.60 Cisplatin/Carboplatin Cross-Resistance in Ovarian Cancer Gore, M.;Fryatt, I.;Wiltshaw, E.;Dawson, T.;Robbinson, B.;Calvert, A.
  21. Jpn. J. Cancer Res. v.81 Possible Mechanisms of Resistance to cis-Diamine (1,1-cyclobutanedicar-boxylato) Platinum(II) of Human Ovarian Cancer Cells Kikuchi, Y.;Iwano, I.;Miyauchi, M.;Kita, T.;Sugita, M.;Tenjin, Y.;Nagata, I.
  22. Science v.93 Inhibition of induced tumors in mice by various vitamins Kensler, G. I.;Sugiura, K.;Young, N. F.;Halter, C. R.;Rhodas, C. P.
  23. Nutrition and Cancer v.7 Comparison of riboflavin, Vitamine A and zinc status of Chinese populations at high and low risk for oesophageal cancer Thurnham, D. I.;Zheng, S. F.;Munoz, N.;Crespi, M.;Grassi, A.;Hambridge, M.;Chai, T. F.
  24. Vopr. Onkol. v.36 no.5 The effect of riboflavin, molybdenum, selenium and zinc on the development of induced tumors of esophagus and forestomach in rats Bespalov, V. G.;Troian, D. N.;Petrov, A. S.;Aleksandrov, V.A.
  25. Chem. Toxic. v.31 no.10 Effects of Riboflavin deficiency and Riboflavin administration on Carcinogen-DNA binding Pangekar, J.;Krishnaswamy, K.;Jagadeesan, V.
  26. Proc. Chin. Acad. Med. Sci. Peking Union Med. Coll. v.5 no.3 Studies on medicamentous inhibitory theraphy for esophageal precancerous lesions 3- and 5- year inhibitory effects of antitumor-B, retinamide and riboflavin Lin, P.;Zhang, J.;Rong, Z.;Han, R.;Xu, S.;Gao, R.;Ding, Z.;Wang, J.;Feng, H.;Cao, S.
  27. Chem. Pharm. Bull. v.36 no.5 Synthesis and Antitumor Activity of Riboflavin and Flavin Mononucleotide Pt(II) Complexes Suzuki,K.;Noji,M.;Tashiro,T.;Kidani,Y.
  28. Cancer Res. v.55 no.21 Riboflavin-mediated photosensitization of Vinca alkaloids distorts durg sensitivity assays Granzow, C.;Kopun, M.;Krober, T.
  29. 숙명여자대학교 약학연구소논문집 v.16 리보플라빈을 가진 수용성 백금(II)착체의 합성과 항암활성 및 세포주기와의 관계 권영이;황규자
  30. J. Med. Chem. v.37 no.10 Synthesis and Antitumor Activity of a Series of [2-substituted-4,5-bis (aminomethyl)-1,3-dioxolane] Pt(II) Complexes Kim, D. K.;Kim, G.;Gam, J.;Cho, Y. B.;Kim, H. T.;Tai, J. H.;Kim ,K. H.;Hong, W. S.;Park, J. G.
  31. Chem. Pharm. Bull. v.37 Synthesis and Antitumor Activity of Alky-1,4-butane-diamine Pt(II) Complexes Having Seven-membered Ring Structure Nowatari, H.;Kuroda, Y.;Hayami, H.;Okamoto, K.;Ekimoto, H.;Takahashi, K.
  32. Chemotherapy (Tokyo) v.38 In Vitro Antitumor Activity of a New Platinum Analogue, NK-121 against Fresh Human Tumor Cells and Established Tumor Cell Lines by Succinate Dehydrogenase Inhibition Test Yamaue, H.;Tanimura, H.;Tani, M.;Iwahashi, M.;Tsunoda, T.